In the context of a combinatorial in vivo pre-clinical study, administration of apigenin in association with an E7-HSP70 DNA vaccine has been shown to increase the levels of primary and memory E7-specific CD8+ T cells, leading to therapeutic anti-tumor effects against E7-expressing tumors in TC-1 tumor-bearing mice [58]. Here, CD8A is linked to neoplasm.